GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Bombesin-like peptides stimulate growth hormone secretion mediated by the gastrin-releasing peptide receptor in cattle.
Zhao. Hongqiong H; Matsuda. Seinosuke S; Thanthan. Sint S; Yannaing. Swe S; Kuwayama. Hideto H
Key Findings
- Neuromedin C (a bombesin‑like peptide) increased plasma GH in cattle in a dose‑dependent way, with 1 µg/kg being the lowest effective dose.
- The GH rise from neuromedin C was completely blocked by a GRP‑receptor antagonist, showing the effect is mediated by the GRP receptor.
- A GHS‑R1a antagonist ([d‑Lys(3)]‑GHRP‑6) did not block the GH increase, and ghrelin levels stayed unchanged; the effect was not seen in rats.
Practical Outcomes
- For biohackers, this study indicates that the GH‑boosting action of bombesin‑like peptides in cattle works via a different receptor than the one targeted by GHRP‑6 in humans, so it doesn’t provide a new dosing strategy or safety data for human use. It’s mainly a mechanistic animal finding with limited direct relevance to everyday peptide protocols.
Summary
In cows, a bombesin‑like peptide called neuromedin C raises growth hormone levels, but it does this through the gastrin‑releasing peptide (GRP) receptor, not the ghrelin (GHS‑R1a) pathway that GHRP‑6 uses in humans. Blocking the GRP receptor stopped the hormone rise, while blocking the ghrelin receptor did not. The study was done in cattle (and a few rats) and didn’t test GHRP‑6 itself, so it offers little direct guidance for human self‑experimenters.
Abstract
This study was designed to determine the effects of bombesin-like peptides (BLPs) on the secretion of growth hormone (GH) and to characterize the receptor subtypes mediating these effects in cattle. Four experiments were conducted: (1) six steers were randomly assigned to receive intravenous (IV) bolus injections of 0, 0.2, 1.0, 12.5 and 50.0 μg/kg neuromedin C (NMC); (2) seven pre-weaned calves were IV injected with 1.0 μg/kg NMC; (3) six steers were IV injected with 2.5μg/kg bovine gastrin-releasing peptide (GRP), 1.0 μg/kg NMC combined with 20.0 μg/kg [d-Lys(3)]-GHRP-6 (an antagonist for the GH secretagogue receptor type 1a [GHS-R1a]), 1.0 μg/kg NMC combined with 20.0 μg/kg N-acetyl-GRP(20-26)-OCH(2)CH(3) (N-GRP-EE, an antagonist for the GRP receptor), 20.0 μg/kg N-GRP-EE alone, 1.0 μg/kg neuromedin B (NMB); and (4) four rats were IV injected 1.0 μg/kg NMC. A serial blood sample was collected before and after injection. Plasma GH levels dose-dependently increased at 5 min after NMC injection and the minimal effective dose was 1.0 μg/kg. Plasma GH level was elevated by GRP, but not by NMB. The NMC-induced elevation of GH was completely blocked by N-GRP-EE. The administration of NMC elevated GH level in pre-weaned calves but not in rats. Ghrelin level was unaffected by any treatments; and [d-Lys(3)]-GHRP-6 did not block the NMC-induced elevation of GH. The results indicate BLP-induced elevation of GH levels is mediated by the GRP receptor but not through a ghrelin/GHS-R1a pathway in cattle.
Study Information
pubmed
2012
2012-07-31T00:00:00.000Z
10.1016/j.peptides.2012.07.018
4
38